Answer
Tildrakizumab has a half-life of 23.4 days (23% coefficient of variation) in people with plaque psoriasis.
Sources for this answer
- Ilumetri 100 mg solution for injection in pre-filled syringeAlmirall Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 7Document updated
Sources checked